We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+25.43%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$16.7B
AUM Growth
+$1.38B
Cap. Flow
-$374M
Cap. Flow %
-2.25%
Top 10 Hldgs %
86.98%
Holding
128
New
13
Increased
17
Reduced
8
Closed
15

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$37.7M
2
PRME icon
Prime Medicine
PRME
+$18.6M
3
DNLI icon
Denali Therapeutics
DNLI
+$14.9M
4
REPL icon
Replimune Group
REPL
+$14.2M
5
SPRY icon
ARS Pharmaceuticals
SPRY
+$13M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$254M
2
CCXI
ChemoCentryx, Inc.
CCXI
+$92.6M
3
TVTX icon
Travere Therapeutics
TVTX
+$44M
4
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$37.6M
5
RLMD icon
Relmada Therapeutics
RLMD
+$18.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.83%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TARA icon
101
Protara Therapeutics
TARA
$228M
$535K ﹤0.01%
199,671
– –
GTH
102
DELISTED
Genetron Holdings Limited ADS
GTH
$510K ﹤0.01%
151,769
– –
KZR
103
DELISTED
Kezar Life Sciences
KZR
$436K ﹤0.01%
6,195
– –
INSM icon
104
Insmed
INSM
$27.5B
$399K ﹤0.01%
19,950
– –
FHTX icon
105
Foghorn Therapeutics
FHTX
$420M
$287K ﹤0.01%
45,027
– –
SERA icon
106
Sera Prognostics
SERA
$84.4M
$254K ﹤0.01%
201,562
– –
CYPH
107
Cypherpunk Technologies Inc
CYPH
$153M
$252K ﹤0.01%
55,971
– –
VINC
108
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$246K ﹤0.01%
12,069
– –
BLCM
109
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$179K ﹤0.01%
249,123
– –
SRZNW
110
DELISTED
Surrozen Inc Warrant
SRZNW
$45.9K ﹤0.01%
833,333
– –
ATYR
111
aTyr Pharma
ATYR
$49.2M
$18.8K ﹤0.01%
8,565
-192,796
-96% -$455K
ALKS icon
112
Alkermes
ALKS
$8.11B
– –
-815,016
Closed -$18.2M
ALLK
113
DELISTED
Allakos
ALLK
– –
-703,050
Closed -$4.3M
AMRN
114
Amarin Corp
AMRN
$298M
– –
-268,856
Closed -$5.86M
CRNX icon
115
Crinetics Pharmaceuticals
CRNX
$8.99B
– –
-735,716
Closed -$14.4M
FLGT icon
116
Fulgent Genetics
FLGT
$548M
– –
-166,619
Closed -$6.35M
RLMD icon
117
Relmada Therapeutics
RLMD
$494M
– –
-495,113
Closed -$18.3M
SNDX icon
118
Syndax Pharmaceuticals
SNDX
$1.75B
– –
-110,729
Closed -$2.66M
SRZN icon
119
Surrozen
SRZN
$282M
– –
-166,667
Closed -$5.05M
EIGR
120
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-17,995
Closed -$4.07M
TCDA
121
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-1,320,290
Closed -$13.8M
OTIC
122
DELISTED
Otonomy, Inc.
OTIC
– –
-8,443,134
Closed -$2.49M
LOGC
123
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
– –
-139,105
Closed -$38K
CCXI
124
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-1,792,657
Closed -$92.6M
FMTX
125
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
– –
-1,886,760
Closed -$37.6M
2 3 4
5
6

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q4 2022 Portfolio in Review

As of Q4 2022, Julian Baker held 128 positions worth $16.7B, up 9.1% from $15.3B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Julian Baker's Q4 2022 filing shows 13 new, 17 increased, 8 reduced and 15 closed positions. Its largest new stake was SpringWorks Therapeutics: 1,528,538 shares worth $39.8M. The largest sale was Global Blood Therapeutics, Inc., an estimated $254M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q4 2022 buy was SpringWorks Therapeutics: 1,528,538 shares worth $39.8M.
  • Julian Baker added most to Denali Therapeutics in Q4 2022, an estimated $14.9M increase.
  • Julian Baker's biggest Q4 2022 reduction was Travere Therapeutics, cutting an estimated $44M.
  • Julian Baker fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $254M.
  • Julian Baker's ten largest holdings make up 87% of its $16.7B portfolio in Q4 2022.
  • Julian Baker opened 13 new positions and closed 15 in Q4 2022.
  • Julian Baker's portfolio value rose 9.1% quarter-over-quarter to $16.7B.

Based on Baker Bros. Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.